Summary of Study ST000783

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000569. The data can be accessed directly via it's Project DOI: 10.21228/M8437T This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis | Show all samples | Show named metabolites | Download named metabolite data
Download mwTab file (text) | Download mwTab file(JSON)

Study ID	ST000783
Study Title	Absolute Quantification of 180 metabolites in serum from african american and european american in prostate cancer and case control samples
Study Summary	Metabolite concentrations were obtained in prostate cancer and case control plasma samples from AA and EA individuals using the AbsoluteIDQ kit p180 (Biocrates Life Science AG, Austria) according to the manufacturer’s instructions. The analysis was performed using a QTRAP 6500 LC/MS/MS System (AB SCIEX, USA) equipped with an electrospray ionization source, Agilent G1367B autosampler and the Analyst 1.51 software (AB SCIEX, USA).
Institute	Baylor College of Medicine
Last Name	Sreekumar
First Name	Arun
Address	One Baylor Plaza, Houston, TX, 77030, USA
Email	Arun.Sreekumar@bcm.edu
Phone	713-798-3305
Submit Date	2017-05-18
Analysis Type Detail	FIA-MS
Release Date	2019-07-17
Release Version	1

Select appropriate tab below to view additional metadata details:

Project:

Project ID:	PR000569
Project DOI:	doi: 10.21228/M8437T
Project Title:	Serum metabolomics study of prostate cancer for african american
Project Summary:	We studied the metabolome in a group of AA and EA of prostate cancer and case control plasma.
Institute:	Baylor College of Medicine
Last Name:	Sreekumar
First Name:	Arun
Address:	One Baylor Plaza, Houston, TX, 77030, USA
Email:	Arun.Sreekumar@bcm.edu
Phone:	713-798-3305

Subject:

Subject ID:	SU000806
Subject Type:	human
Subject Species:	Homo sapiens
Taxonomy ID:	9606
Species Group:	Human

Factors:

Subject type: human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id	local_sample_id	Status
SA042631	19622	Case control \| RACE:AA
SA042632	19843	Case control \| RACE:AA
SA042633	19869	Case control \| RACE:AA
SA042634	19224	Case control \| RACE:AA
SA042635	18717	Case control \| RACE:AA
SA042636	18489	Case control \| RACE:AA
SA042637	18664	Case control \| RACE:AA
SA042638	20049	Case control \| RACE:AA
SA042639	18783	Case control \| RACE:AA
SA042640	20070	Case control \| RACE:AA
SA042641	20323	Case control \| RACE:AA
SA042642	20361	Case control \| RACE:AA
SA042643	20752	Case control \| RACE:AA
SA042644	20319	Case control \| RACE:AA
SA042645	20103	Case control \| RACE:AA
SA042646	18415	Case control \| RACE:AA
SA042647	20078	Case control \| RACE:AA
SA042648	20099	Case control \| RACE:AA
SA042649	20051	Case control \| RACE:AA
SA042650	18665	Case control \| RACE:AA
SA042651	18137	Case control \| RACE:AA
SA042652	18140	Case control \| RACE:AA
SA042653	18013	Case control \| RACE:AA
SA042654	18014	Case control \| RACE:AA
SA042655	18004	Case control \| RACE:AA
SA042656	17962	Case control \| RACE:EA
SA042657	18580	Case control \| RACE:EA
SA042658	18559	Case control \| RACE:EA
SA042659	17893	Case control \| RACE:EA
SA042660	18638	Case control \| RACE:EA
SA042661	18154	Case control \| RACE:EA
SA042662	18072	Case control \| RACE:EA
SA042663	18062	Case control \| RACE:EA
SA042664	18796	Case control \| RACE:EA
SA042665	18035	Case control \| RACE:EA
SA042666	18702	Case control \| RACE:EA
SA042667	18077	Case control \| RACE:EA
SA042668	17848	Case control \| RACE:EA
SA042669	19237	Case control \| RACE:EA
SA042670	18265	Case control \| RACE:EA
SA042671	18402	Case control \| RACE:EA
SA042672	18277	Case control \| RACE:EA
SA042673	18323	Case control \| RACE:EA
SA042674	18404	Case control \| RACE:EA
SA042675	18285	Case control \| RACE:EA
SA042676	19464	Case control \| RACE:EA
SA042677	19255	Case control \| RACE:EA
SA042678	18250	Case control \| RACE:EA
SA042679	18463	Case control \| RACE:EA
SA042680	18225	Case control \| RACE:EA
SA042681	19144	Prostate cancer \| RACE:AA
SA042682	19678	Prostate cancer \| RACE:AA
SA042683	19924	Prostate cancer \| RACE:AA
SA042684	19502	Prostate cancer \| RACE:AA
SA042685	19515	Prostate cancer \| RACE:AA
SA042686	19901	Prostate cancer \| RACE:AA
SA042687	19838	Prostate cancer \| RACE:AA
SA042688	19766	Prostate cancer \| RACE:AA
SA042689	17985	Prostate cancer \| RACE:AA
SA042690	18515	Prostate cancer \| RACE:AA
SA042691	18517	Prostate cancer \| RACE:AA
SA042692	18183	Prostate cancer \| RACE:AA
SA042693	18414	Prostate cancer \| RACE:AA
SA042694	18302	Prostate cancer \| RACE:AA
SA042695	18331	Prostate cancer \| RACE:AA
SA042696	18970	Prostate cancer \| RACE:AA
SA042697	18538	Prostate cancer \| RACE:AA
SA042698	18939	Prostate cancer \| RACE:AA
SA042699	18893	Prostate cancer \| RACE:AA
SA042700	15298	Prostate cancer \| RACE:AA
SA042701	18567	Prostate cancer \| RACE:AA
SA042702	18177	Prostate cancer \| RACE:AA
SA042703	17585	Prostate cancer \| RACE:EA
SA042704	19655	Prostate cancer \| RACE:EA
SA042705	18109	Prostate cancer \| RACE:EA
SA042706	19001	Prostate cancer \| RACE:EA
SA042707	18865	Prostate cancer \| RACE:EA
SA042708	18228	Prostate cancer \| RACE:EA
SA042709	19023	Prostate cancer \| RACE:EA
SA042710	18669	Prostate cancer \| RACE:EA
SA042711	18596	Prostate cancer \| RACE:EA
SA042712	18262	Prostate cancer \| RACE:EA
SA042713	18542	Prostate cancer \| RACE:EA
SA042714	18557	Prostate cancer \| RACE:EA
SA042715	19084	Prostate cancer \| RACE:EA
SA042716	19093	Prostate cancer \| RACE:EA
SA042717	19243	Prostate cancer \| RACE:EA
SA042718	19575	Prostate cancer \| RACE:EA
SA042719	18130	Prostate cancer \| RACE:EA
SA042720	19189	Prostate cancer \| RACE:EA
SA042721	19168	Prostate cancer \| RACE:EA
SA042722	19113	Prostate cancer \| RACE:EA
SA042723	19157	Prostate cancer \| RACE:EA
SA042724	19648	Prostate cancer \| RACE:EA

Showing results 1 to 94 of 94

Showing results 1 to 94 of 94

Collection:

Collection ID:	CO000800
Collection Summary:	Clinically annotated ancestry verified serum samples from the National Cancer Institute.
Sample Type:	Blood

Treatment:

Treatment ID:	TR000820
Treatment Summary:	NA

Sample Preparation:

Sampleprep ID:	SP000813
Sampleprep Summary:	Briefly, 10 μl of undiluted plasma sample from each patient or control individual was placed in individual wells of a 96 well plate provided by the manufacturer. Samples were dried at room temperature using a nitrogen evaporator drying unit for 30 mins. Following this, 20 μl of 5% phenylisothiocyanate (PITC) reagent was added to the dried plasma spots and incubated for 20 min at RT. The plate was again dried under the nitrogen evaporator for 60 mins. Next, 300 μl of 5 mM ammonium acetate in methanol was added to each well and the mixture was incubated on a shaker (450 rpm) for 30 mins. The plate was then centrifuged at 100 g for 2 min resulting in a volume of ~ 250 μl sample in the plate (labeled as Flow injection or FIA plate). 150 μl of the sample was subsequently transferred from the FIA plate into a second plate (termed LC-MS plate). In total, all the samples were analyzed in three batches, each containing one FIA and LC-MS plate, respectively. 150 μl HPLC grade water was added to the LC-MS plate to make up the volume to 300 ul. In parallel, 500 μl of mass spectrometry injection solvent (stock solution provided by Biocrates was diluted in methanol) was added to the FIA plate. The LC-MS plate was analyzed using Multiple Reaction Monitoring post LC-MS fractionation. The FIA plate was stored at 4°C until the LC-MS plate was completed assayed.

Sampleprep ID:

SP000813

Sampleprep Summary:

Briefly, 10 μl of undiluted plasma sample from each patient or control individual was placed in individual wells of a 96 well plate provided by the manufacturer. Samples were dried at room temperature using a nitrogen evaporator drying unit for 30 mins. Following this, 20 μl of 5% phenylisothiocyanate (PITC) reagent was added to the dried plasma spots and incubated for 20 min at RT. The plate was again dried under the nitrogen evaporator for 60 mins. Next, 300 μl of 5 mM ammonium acetate in methanol was added to each well and the mixture was incubated on a shaker (450 rpm) for 30 mins. The plate was then centrifuged at 100 g for 2 min resulting in a volume of ~ 250 μl sample in the plate (labeled as Flow injection or FIA plate). 150 μl of the sample was subsequently transferred from the FIA plate into a second plate (termed LC-MS plate). In total, all the samples were analyzed in three batches, each containing one FIA and LC-MS plate, respectively. 150 μl HPLC grade water was added to the LC-MS plate to make up the volume to 300 ul. In parallel, 500 μl of mass spectrometry injection solvent (stock solution provided by Biocrates was diluted in methanol) was added to the FIA plate. The LC-MS plate was analyzed using Multiple Reaction Monitoring post LC-MS fractionation. The FIA plate was stored at 4°C until the LC-MS plate was completed assayed.

Combined analysis:

Analysis ID	AN001239
Analysis type	MS
Chromatography type	None (Direct infusion)
Chromatography system	None
Column	none
MS Type	ESI
MS instrument type	Triple quadrupole
MS instrument name	AB Sciex 6500 QTRAP LC-MS/MS
Ion Mode	POSITIVE
Units	uM

Chromatography:

Chromatography ID:	CH000866
Chromatography Summary:	Flow injection coupled to MRM was used to measure mono-unsaturated glycerophosphophocholines in samples in the FIA plate. For flow injection analysis, 20 μl of sample was injected directly into the MS at a flow rate of 30 μl/min in mobile phase.
Instrument Name:	None
Column Name:	none
Chromatography Type:	None (Direct infusion)

MS:

MS ID:	MS001133
Analysis ID:	AN001239
Instrument Name:	AB Sciex 6500 QTRAP LC-MS/MS
Instrument Type:	Triple quadrupole
MS Type:	ESI
Ion Mode:	POSITIVE